The indication for the HIV-1 treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide, B/F/TAF) has been expanded to include children and adolescents aged 6 years and older.

Gilead Sciences Korea announced on the 23rd that its Biktarvy has been approved by the Ministry of Food and Drug Safety for the treatment of HIV-1 infection in children or adolescents 6 years of age and older.

The approval allows Biktarvy’s use in adults and pediatric patients aged 6 years and older weighing 25 kg or more who are antiretroviral treatment-naïve or who have achieved stable viral suppression (HIV-1 RNA <50 copies/mL) for at least 3 months without failure of an existing antiretroviral tr